A5070358745- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Melanoma and MAPK Pathways
- Lung Cancer Research Studies
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Gallbladder and Bile Duct Disorders
- Cancer Genomics and Diagnostics
- Metastasis and carcinoma case studies
- Cutaneous Melanoma Detection and Management
- Peptidase Inhibition and Analysis
- Computational Drug Discovery Methods
- Radiomics and Machine Learning in Medical Imaging
University of Modena and Reggio Emilia
2016-2025
Policlinico di Modena
2014-2023
Azienda USL di Bologna
2021
Istituto Oncologico Veneto
2018
University of Lausanne
2018
Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the cohort of CheckMate-142, largest single-study report an immunotherapy combination...
In the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety profile in previously treated patients microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) at 13.4- 25.4-month median follow-up (Overman MJ, Lonardi S, Wong KYM et al. Durable DNA mismatch repair-deficient/microsatellite instability-high cancer. J Clin Oncol. 2018;36:773-779....
Abstract Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies currently lacking. Using whole-genome analysis of 37 metastatic colorectal (mCRC) treated the chemotherapy trifluridine/tipiracil (FTD/TPI), we identified KRAS codon G12 ( ) mutations as a potential biomarker resistance. Next, collected real-world data 960 mCRC receiving FTD/TPI and validated that were significantly associated poor survival, also in...
// Alessandro Passardi 1, * , Emanuela Scarpi 2, Luigi Cavanna 3 Monia Dall'Agata 2 Davide Tassinari 4 Silvana Leo 5 Ilaria Bernardini 6 Fabio Gelsomino 7 Stefano Tamberi 8 Alba A. Brandes 9 Elena Tenti 10 Roberto Vespignani 11 Giovanni L. Frassineti 1 Dino Amadori Ugo De Giorgi Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy Unit Biostatistics and Clinical Trials, IRST Oncology Unit, Guglielmo da Saliceto...
Abstract Purpose: BRAF mutations are grouped in activating RAS-independent signaling as monomers (class 1–V600E) or dimers 2–codons 597/601), and RAS-dependent with impaired kinase activity 3–codons 594/596). Although clinical, pathologic, molecular features of V600EBRAF-mutated metastatic colorectal cancer (mCRC) well known, limited data available from the two other classes. Experimental Design: Data 117 patients (92 class 1, 12 2, 13 3)-mutated mCRC were collected. A total 540 wt mCRCs...
<h3>Importance</h3> Data about the optimal timing for initiation of peptide receptor radionuclide therapy (PRRT) advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. <h3>Objective</h3> To evaluate association upfront PRRT vs chemotherapy or targeted with progression-free survival (PFS) among patients advanced who experienced disease progression after treatment somatostatin analogues (SSAs). <h3>Design, Setting, and Participants</h3> This retrospective,...
Background Programmed death-1 (PD-1) inhibitors, including nivolumab, have demonstrated long-term survival benefit in previously treated patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (CRC). PD-1 and lymphocyte-activation gene 3 (LAG-3) are distinct immune checkpoints that often co-expressed on tumor-infiltrating lymphocytes contribute to tumor-mediated T-cell dysfunction. Relatlimab is a LAG-3 inhibitor has efficacy...
<b><i>Purpose:</i></b> The role of chemotherapy in low-/intermediate-grade neuroendocrine tumors (NETs) is still debated. We present the results an Italian multicenter retrospective study evaluating activity and toxicity oxaliplatin-based patients with advanced NETs. <b><i>Methods:</i></b> Clinical records from 5 referral centers were reviewed. Disease control rate (DCR) corresponding to PR + SD (partial response stable disease) at 6 months,...
553 Background: Nivolumab (NIVO) provided durable responses (investigator-assessed [INV] ORR, 31%) and disease control (DCR, 69%) in pretreated pts with dMMR/MSI-H mCRC CheckMate-142 (NCT02060188; Overman et al Lancet Oncol 2017). An interim analysis of the NIVO + ipilimumab (IPI) combination cohort reported a preliminary ORR 55% manageable safety profile subset (n = 84) ≥ 6 mo follow-up (André ASCO Here we report for first time efficacy from complete population (N 119) IPI CheckMate-142,...
Objective: The aim of this study was to evaluate clinical and morphological features related nodal involvement in appendiceal neuroendocrine tumors (NETs), identify patients who should be referred for oncological radicalization with hemicolectomy. Background: Appendiceal NETs are usually diagnosed accidentally after appendectomy; the indications right hemicolectomy currently based on several parameters (ie, tumor size, grading, proliferative index, localization, mesoappendiceal invasion,...
Abstract Background An accurate risk‐stratification is key to optimize the benefit‐to‐risk ratio of palliative treatment in advanced biliary cancer. We aimed at assessing impact prognostic nutritional index (PNI) on survival and response cancer (ABC) receiving first‐line chemotherapy. Methods Medical records ABC treated with standard chemotherapy Modena Cancer Centre were retrospectively reviewed for variables deemed potential interest, including PNI. Univariate multivariate analyses...
554 Background: Nivolumab (NIVO) provided durable responses (ORR, 32% per central assessment) and disease control (DCR, 64%) in pre-treated pts with dMMR/MSI-H mCRC (NCT02060188; Overman MJ et al Lancet Oncol 2017). NIVO was approved the US for who progress after standard chemotherapy (SC) a fluoropyrimidine (F), oxaliplatin (Ox), irinotecan (Iri). Here we present long-term survival outcomes by prior CheckMate-142. Methods: Pts received 3 mg/kg Q2W. The primary endpoint ORR RECIST 1.1. Other...
4040 Background: In the phase 2 CheckMate 142 trial, NIVO + low-dose IPI had robust, durable clinical benefit and was well tolerated as 1L therapy for MSI-H/dMMR mCRC (median follow-up 13.8 months [mo; range, 9–19]; Lenz et al. Ann Oncol 2018;29:LBA18). Longer is presented here. Methods: Patients (pts) with no prior treatment metastatic disease received 3 mg/kg Q2W 1 Q6W until progression or discontinuation. The primary endpoint investigator-assessed (INV) objective response rate (ORR) per...
This study investigated the efficacy of chemoradiotherapy (CRT) followed by durvalumab as neoadjuvant therapy locally advanced rectal cancer.The PANDORA trial is a prospective, phase II, open-label, single-arm, multicenter aimed at evaluating and safety preoperative treatment with (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 administered 825 mg/m2 twice daily). The primary...
Objective Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that pretreatment molecular profiles diagnostic biopsies can predict patient benefit from chemotherapy and define bases innate chemoresistance. Design identified a cohort iCCA comparable baseline characteristics who diverged as extreme outliers on (survival <6 m in rapid progressors, RP; survival >23 long...
Background: The optimal treatment sequencing for advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) is unknown. We performed a multicenter, retrospective study to evaluate the best sequence in terms of progression-free survival first-line (PFS1) and second-line (PFS2), overall among patients with pNETs. Methods: This multicenter retrospectively analyzed prospectively collected data sporadic pNETs who received at least two consecutive therapeutic lines, evidence...
Abstract Background Lung neuroendocrine neoplasms (NENs) represent about 20% of all lung cancers. Few therapeutic options are available for atypical carcinoids (ACs). Single-agent temozolomide (TEM) is active in NENs, but whether the addition capecitabine (CAPTEM) associated with improved outcomes, unknown. We sought to investigate TEM-based therapies (TEM or CAPTEM) patients advanced AC. Material and methods This was a retrospective analysis prospectively collected data from AC referred our...
Highlights•The oral factor Xa inhibitors are effective and safe in VTE treatment.•Cancer patients, especially during active treatment may develop VTE.•A low rate of AEs edoxaban related with an impact on antineoplastic therapy was observed.•More than the half occurred first 30 days.•Edoxaban-related did not result a lower overall QoL patients.AbstractBackgroundThe inhibitor, edoxaban, is cancer-associated Venous Thromboembolism (VTE) treatment. The EDOI study aims to evaluate compliance...